Loading…
Loading…
As the market faces more and more concentration risk from the dominance of just a few AI hyperscalers, investors are on the lookout for ETF tools to diversify their portfolios while still chasing upside.
Fidelity Disruptive Technology ETF (FDTX) earns a Buy for its concentrated, actively managed exposure to leading AI infrastructure and compute names. FDTX's top holdings—TSM, NVDA, MSFT, AMZN, GOOG, META—anchor it at the upper end of the AI value chain, driving recent outperformance. The fund's 0.50% expense ratio is competitive for active management, and its 42% turnover signals disciplined, thesis-driven portfolio construction.
If you searched for a biotech or health sciences ETF and landed on Fidelity Disruptive Technology ETF (NYSEARCA:FDTX), there is something important to clarify upfront: this fund carries zero healthcare sector exposure.
Disruptive technology is manifesting in heavier use of artificial intelligence (AI), machine learning, robotics, and other advancements. This is creating the need to adjust regulations at the federal and state levels.
There are thousands of exchange-traded funds available in the market today. While having multiple options is great, it can also become difficult to choose the right one.
AI investing remains a top priority for investors ahead of 2026. Finding the right way into that trend, however, is the real task.
Fidelity Disruptive Technology ETF (NASDAQ: FDTX - Get Free Report) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totaling 2,223 shares, a growth of 204.5% from the November 30th total of 730 shares. Currently, 0.0% of the company's stock are short
Fidelity Investment's suite of disruptive ETFs are designed to capture growth opportunities arising from groundbreaking innovation and transformative technologies.
SEC filings for FDTX aren't indexed yet — common for recently launched funds. Browse the issuer's filings on SEC EDGAR directly.